High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer

British Journal of Cancer

Volumn 100, Issue 10, 2009, Pages 1540-1548

  Gaber, A ^a   Johansson, M ^a   Stenman, U H ^b   Hotakainen, K ^b   Ponten F ^c   Glimelius, B ^d,e   Bjartell, A ^a   Jirstrom K ^a   Birgisson, H ^d  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UPPSALA UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Colorectal cancer; Liver metastasis; Prognosis; TATI

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TRYPSIN INHIBITOR; TUMOUR ASSOCIATED TRYPSIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TRYPSIN INHIBITOR, KAZAL PANCREATIC; UP-REGULATION;

EID: 67349251220     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605047     Document Type: Article

References (52)

1. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P (1990) A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348: 699-704
2. Brennan DJ, Rexhepaj E, O'Brien SL, McSherry E, O'Connor DP, Fagan A, Culhane AC, Higgins DG, Jirstrom K, Millikan RC, Landberg G, Duffy MJ, Hewitt SM, Gallagher WM (2008) Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 14: 2681-2689
3. Catarino M, Conde R (1991) Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA. Scand J Clin Lab Invest 207: 43 - 46
4. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (NY) 295: 2387-2392
5. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H (2003) Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA 100: 5778-5782
6. Emi M, Nakamura Y, Ogawa M, Yamamoto T, Nishide T, Mori T, Matsubara K (1986) Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens. Gene 41: 305-310
7. Freeman TC, Playford RJ, Quinn C, Beardshall K, Poulter L, Young J, Calam J (1990) Pancreatic secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice. Gut 31: 1318-1323
8. Fritz H, Hutzel M, Werle E (1967) (On protease inhibitors, VI. On the identity of the protease inhibitor from rat liver with the trypsin-kallikren- inhibitor (Trasylol)). Hoppe-Seyler's Zeitschrift für physiologische Chemie 348: 950
9. Gouyer V, Fontaine D, Dumont P, de Wever O, Fontayne-Devaud H, Leteurtre E, Truant S, Delacour D, Drobecq H, Kerckaert JP, de Launoit Y, Bracke M, Gespach C, Desseyn JL, Huet G (2008) Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells. Oncogene 27: 4024 - 4033
10. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
11. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, Brunner N, Stephens RW (1999) Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 80: 495-503
12. Hotakainen K, Bjartell A, Sankila A, Jarvinen R, Paju A, Rintala E, Haglund C, Stenman UH (2006) Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int J Oncol 28: 95-101
13. Huhtala ML, Pesonen K, Kalkkinen N, Stenman UH (1982) Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 257: 13713-13716
14. Kelloniemi E, Rintala E, Finne P, Stenman UH (2003) trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology 62: 249-253
15. Kohn EC, Liotta LA (1995) Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 55: 1856-1862
16. Koivunen E, Ristimaki A, Ifkonen O, Osman S, Vuento M, Stenman UH (1991) Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res 51: 2107-2112
17. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847
18. Koshikawa N, Hasegawa S, Nagashima Y, Mitsuhashi K, Tsubota Y, Miyata S, Miyagi Y, Yasumitsu H, Miyazaki K (1998) Expression of trypsin by epithelial cells of various tissues, leukocytes, and neurons in human and mouse. Am J Pathol 153: 937-944
19. Kruger A, Soeltl R, Sopov I, Kopitz C, Arlt M, Magdolen V, Harbeck N, Gansbacher B, Schmitt M (2001) Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 61: 1272-1275
20. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH, Hsu HC (2007) Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer 43: 736-744
21. Marchbank T, Chinery R, Hanby AM, Poulsom R, Elia G, Playford RJ (1996) Distribution and expression of pancreatic secretory trypsin inhibitor and its possible role in epithelial restitution. Am J Pathol 148: 715-722
22. Marchbank T, Freeman TC, Playford RJ (1998) Human pancreatic secretory trypsin inhibitor. Distribution, actions and possible role in mucosal integrity and repair. Digestion 59: 167-174
23. Mignatti P, Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195
24. Moilanen M, Sorsa T, Stenman M, Nyberg P, Lindy O, Vesterinen J, Paju A, Konttinen YT, Stenman UH, Salo T (2003) Tumor-associated trypsino-gen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry 42: 5414-5420
25. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, Seymour L (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21: 3296-3302
26. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149
27. Nielsen HJ, Pappot H, Christensen IJ, Brunner N, Thorlacius-Ussing O, Moesgaard F, Dano K, Grondahl-Hansen J (1998) Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ (Clin Res Ed) 316: 829-830
28. Osman S, Turpeinen U, Itkonen O, Stenman UH (1993) Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods 161: 97-106
29. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, Hemminki A, Stenman UH, Bjartell A (2007) Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rvl cells. Eur Urol 52: 1670-1679
30. Paju A, Jacobsen J, Rasmuson T, Stenman UH, Ljungberg B (2001) Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma. J Urol 165: 959-962
31. Paju A, Vartiainen J, Haglund C, Itkonen O, von Boguslawski K, Leminen A, Wahlstrom T, Stenman UH (2004) Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res 10: 4761-4768
32. Pasanen P, Eskelinen M, Kulju A, Penttila I, Janatuinen E, Alhava E (1995) Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242. Scand J Clin Lab Invest 55: 119-124
33. Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hansen HH, Dano K, Brunner N (1994) Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54: 120-123
34. Playford RJ, Batten JJ, Freeman TC, Beardshall K, Vesey DA, Fenn GC, Baron JH, Calam J (1991) Gastric output of pancreatic secretory trypsin inhibitor is increased by misoprostol. Gut 32: 1396-1400
35. Punt CJ, Buyse M, Könne CH, Hohenberger P, Labianca R, Schmoll HJ, Pählman L, Sobrero A, Douillard JY (2007) Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials. J Natl Cancer Inst 99: 998 -1003
36. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O (1997) High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 3: 1623-1628
37. Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, Duffy MJ, Jirstrom K, Gallagher WM (2008) Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res 10: R89
38. Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brunner N, Foekens JA (2004) Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 10: 2289-2298
39. Solakidi S, Tiniakos DG, Petraki K, Stathopoulos GP, Markaki I, Androulakis G, Sekeris CE (2003) Co-expression of trypsin and tumour-associated trypsin inhibitor (TATI) in colorectal adenocarcinomas. Histol Histopathol 18: 1181-1188
40. Soreide K (2008) Proteinase-activated receptor 2 (PAR-2) in gastrointestinal and pancreatic pathophysiology, inflammation and neoplasia. Scand J Gastroenterol 43: 902-909
41. Soreide K, Janssen EA, Körner H, Baak JP (2006) Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. J Pathol 209: 147-156
42. Stenman UH (1990) Tumour-associated trypsin inhibitor and tumour-associated trypsin. Scand J Clin Lab Invest 201: 93-101
43. Stenman UH (2002) Tumor-associated trypsin inhibitor. Clin Chem 48: 1206-1209
44. Tani T, Kawashima I, Mita K, Takiguchi Y (1990) Nucleotide sequence of the human pancreatic trypsinogen III cDNA. Nucleic Acids Res 18: 1631
45. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andren O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM (2008) The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer cell 13: 519-528
46. Turpeinen U, Koivunen E, Stenman UH (1988) Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion. Biochem J 254: 911-914
47. Venesmaa P, Lehtovirta P, Stenman UH, Leminen A, Forss M, Ylikorkala O (1994) Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer. Br J Cancer 70: 1188-1190
48. Venesmaa P, Stenman UH, Forss M, Leminen A, Lehtovirta P, Vartiainen J, Paavonen J (1998) Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in Stage III epithelial ovarian cancer. Br J Obstet Gynaecol 105: 508-511
49. Wiegand U, Corbach S, Minn A, Kang J, Muller-Hill B (1993) Cloning of the cDNA encoding human brain trypsinogen and characterization of its product. Gene 136: 167-175
50. Wiksten JP, Lundin J, Nordling S, Kokkola A, Stenman UH, Haglund C (2005) High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. Histopathology 46: 380-388
51. Yamamoto H, Iku S, Adachi Y, Imsumran A, Taniguchi H, Nosho K, Min Y, Horiuchi S, Yoshida M, Itoh F, Imai K (2003) Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol 199: 176-184
52. Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Takemiya S, Yanoma S, Imada T, Noguchi Y (2004) Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer. Anticancer Res 24: 2101-2105